9. REFERENCES
1.Boorjian, S.A., et al. Risk factors and outcomes of urethral recurrence following radical cystectomy. Eur Urol, 2011. 60: 1266.
https://pubmed.ncbi.nlm.nih.gov/21871713/
2.Witjes, J.A., et al. members of the EAU Guidelines Panel on Muscle-invasive and Metastatic Bladder Cancer., Edn. presented at the 38th EAU Annual Congress Milan, in EAU Guidelines 2023: Arnhem. The Netherlands.
https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer
3.Gakis, G., et al. European Association of Urology Guidelines on Primary Urethral Carcinoma-2020 Update. Eur Urol Oncol, 2020. 3: 424.
https://pubmed.ncbi.nlm.nih.gov/32605889/
4.Guyatt, G.H., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 2008. 336: 924.
https://pubmed.ncbi.nlm.nih.gov/18436948/
5.Guyatt, G.H., et al. What is “quality of evidence” and why is it important to clinicians? BMJ, 2008. 336: 995.
https://pubmed.ncbi.nlm.nih.gov/18456631/
6.Phillips, B., et al. Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009.
https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/
7.Guyatt, G.H., et al. Going from evidence to recommendations. BMJ, 2008. 336: 1049.
https://pubmed.ncbi.nlm.nih.gov/18467413/
8.Gatta, G., et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer, 2011. 47: 2493.
https://pubmed.ncbi.nlm.nih.gov/22033323/
9.Brierley, J.D., et al., TNM classification of malignant tumors. UICC International Union Against Cancer. 2017, Wiley/Blackwell. p. 208.
https://www.wiley.com/en-gb/TNM+Classification+of+Malignant+Tumours%2C+8th+Edition-p-
9781119263579
10.RARECARENet. Surveillance of Rare Cancers in Europe. 2019. Access date Dec 2022.
http://www.rarecare.eu/default.asp
11.Wenzel, M., et al. Incidence rates and contemporary trends in primary urethral cancer. Cancer Causes Control, 2021. 32: 627.
https://pubmed.ncbi.nlm.nih.gov/33751293/
12.Wenzel, M., et al. Sex-Related Differences Include Stage, Histology, and Survival in Urethral Cancer Patients. Clin Genitourin Cancer, 2021. 19: 135.
https://pubmed.ncbi.nlm.nih.gov/33526327/
13.Krukowski, J., et al. Primary urethral carcinoma - unexpected cause of urethral stricture. Case report and review of the literature. Med Ultrason, 2019. 21: 494.
https://pubmed.ncbi.nlm.nih.gov/31765461/
14.Guo, H., et al. Lichen Sclerosus Accompanied by Urethral Squamous Cell Carcinoma: A Retrospective Study From a Urethral Referral Center. Am J Mens Health, 2018. 12: 1692.
https://pubmed.ncbi.nlm.nih.gov/29926751/
15.Colapinto, V., et al. Primary carcinoma of the male urethra developing after urethroplasty for stricture. J Urol, 1977. 118: 581.
https://pubmed.ncbi.nlm.nih.gov/916053/
16.Mohanty, N.K., et al. Squamous cell carcinoma of perineal urethrostomy. Urol Int, 1995. 55: 118.
https://pubmed.ncbi.nlm.nih.gov/8533195/
17.Sawczuk, I., et al. Post urethroplasty squamous cell carcinoma. N Y State J Med, 1986. 86: 261.
https://pubmed.ncbi.nlm.nih.gov/3459083/
18.Mohan, H., et al. Squamous cell carcinoma of the prostate. Int J Urol, 2003. 10: 114.
https://pubmed.ncbi.nlm.nih.gov/12588611/
19.Arva, N.C., et al. Diagnostic dilemmas of squamous differentiation in prostate carcinoma case report and review of the literature. Diagn Pathol, 2011. 6: 46.
https://pubmed.ncbi.nlm.nih.gov/21627811/
20.Cupp, M.R., et al. Detection of human papillomavirus DNA in primary squamous cell carcinoma of the male urethra. Urology, 1996. 48: 551.
https://pubmed.ncbi.nlm.nih.gov/8886059/
21.Wiener, J.S., et al. Oncogenic human papillomavirus type 16 is associated with squamous cell cancer of the male urethra. Cancer Res, 1992. 52: 5018.
https://pubmed.ncbi.nlm.nih.gov/1325290/
22.Ahmed, K., et al. Urethral diverticular carcinoma: an overview of current trends in diagnosis and management. Int Urol Nephrol, 2010. 42: 331.
https://pubmed.ncbi.nlm.nih.gov/19649767/
23.Chung, D.E., et al. Urethral diverticula in women: discrepancies between magnetic resonance imaging and surgical findings. J Urol, 2010. 183: 2265.
https://pubmed.ncbi.nlm.nih.gov/20400161/
24.Thomas, A.A., et al. Urethral diverticula in 90 female patients: a study with emphasis on neoplastic alterations. J Urol, 2008. 180: 2463.
https://pubmed.ncbi.nlm.nih.gov/18930487/
25.Libby, B., et al. Non-surgical treatment of primary female urethral cancer. Rare Tumors, 2010. 2: e55.
https://pubmed.ncbi.nlm.nih.gov/21139970/
26.Altman, D., et al. Cancer Risk After Midurethral Sling Surgery Using Polypropylene Mesh. Obstet Gynecol, 2018. 131: 469.
https://pubmed.ncbi.nlm.nih.gov/29420401/
27.Gandhi, J.S., et al. Clear cell adenocarcinoma of the male urethral tract. Indian J Pathol Microbiol, 2012. 55: 245.
https://pubmed.ncbi.nlm.nih.gov/22771656/
28.Mehra, R., et al. Primary urethral clear-cell adenocarcinoma: comprehensive analysis by surgical pathology, cytopathology, and next-generation sequencing. Am J Pathol, 2014. 184: 584.
https://pubmed.ncbi.nlm.nih.gov/24389164/
29.Visser, O., et al. Incidence and survival of rare urogenital cancers in Europe. Eur J Cancer, 2012. 48: 456.
https://pubmed.ncbi.nlm.nih.gov/22119351/
30.Rabbani, F. Prognostic factors in male urethral cancer. Cancer, 2011. 117: 2426.
https://pubmed.ncbi.nlm.nih.gov/24048790/
31.Aleksic, I., et al. Primary urethral carcinoma: A Surveillance, Epidemiology, and End Results data analysis identifying predictors of cancer-specific survival. Urol Ann, 2018. 10: 170.
https://pubmed.ncbi.nlm.nih.gov/29719329/
32.Sui, W., et al. Outcomes and Prognostic Factors of Primary Urethral Cancer. Urology, 2017. 100: 180.
https://pubmed.ncbi.nlm.nih.gov/27720774/
33.Wenzel, M., et al. Epidemiology of Unconventional Histological Subtypes of Urethral Cancer. Urol Int, 2022: 1.
https://pubmed.ncbi.nlm.nih.gov/35882213/
34.Greiman, A.K., et al. Urethral diverticulum: A systematic review. Arab J Urol, 2019. 17: 49.
https://pubmed.ncbi.nlm.nih.gov/31258943/
35.WHO Classification of Tumours, Urinary and Male Genital Tumours. Vol. 5th Edn, Volume 8. 2022.
36.Shanks, J.H., et al. Dataset for reporting of carcinoma of the urethra (in urethrectomy specimens): recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology, 2019. 75: 453.
https://pubmed.ncbi.nlm.nih.gov/31009090/
37.Gheiler, E.L., et al. Management of primary urethral cancer. Urology, 1998. 52: 487.
https://pubmed.ncbi.nlm.nih.gov/9730466/
38.Karnes, R.J., et al. Surgery for urethral cancer. Urol Clin North Am, 2010. 37: 445.
https://pubmed.ncbi.nlm.nih.gov/20674699/
39.Blaivas, J.G., et al. Periurethral masses: etiology and diagnosis in a large series of women. Obstet Gynecol, 2004. 103: 842.
https://pubmed.ncbi.nlm.nih.gov/15121554/
40.Wojcik, E.M., et al. The Paris System for Reporting Urinary Cytology. 2022, Switzerland.
https://link.springer.com/book/10.1007/978-3-030-88686-8
41.Touijer, A.K., et al. Role of voided urine cytology in diagnosing primary urethral carcinoma. Urology, 2004. 63: 33.
https://pubmed.ncbi.nlm.nih.gov/14751342/
42.Gakis, G., et al. Oncological Outcomes of Patients with Concomitant Bladder and Urethral Carcinoma. Urol Int, 2016. 97: 134.
https://pubmed.ncbi.nlm.nih.gov/27462702/
43.Samm, B.J., et al. Penectomy: a technique to reduce blood loss. Urology, 1999. 53: 393.
https://pubmed.ncbi.nlm.nih.gov/9933061/
44.Donat, S.M., et al. The efficacy of transurethral biopsy for predicting the long-term clinical impact of prostatic invasive bladder cancer. J Urol, 2001. 165: 1580.
https://pubmed.ncbi.nlm.nih.gov/11342921/
45.Schubert, T., et al. MP11-20 The predictive accuracy between clinical staging and pathological staging in patients with primary urethral carcinoma. J Urol, 2019. 201: e135.
https://www.auajournals.org/doi/abs/10.1097/01.JU.0000555184.87550.3c
46.Del Gaizo, A., et al. Magnetic resonance imaging of solid urethral and peri-urethral lesions. Insights Imaging, 2013. 4: 461.
https://pubmed.ncbi.nlm.nih.gov/23686749/
47.Itani, M., et al. MRI of female urethra and periurethral pathologies. Int Urogynecol J, 2016. 27: 195.
https://pubmed.ncbi.nlm.nih.gov/26209954/
48.Stewart, S.B., et al. Imaging tumors of the penis and urethra. Urol Clin North Am, 2010. 37: 353.
https://pubmed.ncbi.nlm.nih.gov/20674692/
49.Kim, B., et al. Imaging of the male urethra. Semin Ultrasound CT MR, 2007. 28: 258.
https://pubmed.ncbi.nlm.nih.gov/17874650/
50.Raman, S.P., et al. Upper and Lower Tract Urothelial Imaging Using Computed Tomography Urography. Radiol Clin North Am, 2017. 55: 225.
https://pubmed.ncbi.nlm.nih.gov/28126213/
51.Gourtsoyianni, S., et al. MRI at the completion of chemoradiotherapy can accurately evaluate the extent of disease in women with advanced urethral carcinoma undergoing anterior pelvic exenteration. Clin Radiol, 2011. 66: 1072.
https://pubmed.ncbi.nlm.nih.gov/21839430/
52.Laudicella, R., et al. (18)F-FDG PET/MR Refines Evaluation in Newly Diagnosed Metastatic Urethral Adenocarcinoma. Nucl Med Mol Imaging, 2019. 53: 296.
https://pubmed.ncbi.nlm.nih.gov/31456863/
53.Dayyani, F., et al. Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists. Urol Oncol, 2013. 31: 1171.
https://pubmed.ncbi.nlm.nih.gov/22534087/
54.Gakis, G., et al. Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma. World J Urol, 2016. 34: 97.
https://pubmed.ncbi.nlm.nih.gov/25981402/
55.Werntz, R.P., et al. The role of inguinal lymph node dissection in men with urethral squamous cell carcinoma. Urol Oncol, 2018. 36: 526 e1.
https://pubmed.ncbi.nlm.nih.gov/30446445/
56.Naumann, C.M., et al. Reliability of dynamic sentinel node biopsy combined with ultrasound-guided removal of sonographically suspicious lymph nodes as a diagnostic approach in patients with penile cancer with palpable inguinal lymph nodes. Urol Oncol, 2015. 33: 389.e9.
https://pubmed.ncbi.nlm.nih.gov/25934562/
57.Carroll, P.R., et al. Surgical anatomy of the male and female urethra. Urol Clin North Am, 1992. 19: 339.
https://pubmed.ncbi.nlm.nih.gov/1574824/
58.Sharp, D., et al. Surgery of penile and urethral carcinoma, In: Campbell’s Urology, D. McDougal, A. Wein, L. Kavoussi, A. Novick, A. Partin, C. Peters & P. Ramchandani, Editors. 212, Saunders Elsevier: Philadelphia, PA, USA.
59.Abudurexiti, M., et al. Prognosis of rare pathological primary urethral carcinoma. Cancer Manag Res, 2018. 10: 6815.
https://pubmed.ncbi.nlm.nih.gov/30584373/
60.Swartz, M.A., et al. Incidence of primary urethral carcinoma in the United States. Urology, 2006.
68: 1164.
https://pubmed.ncbi.nlm.nih.gov/17141838/
61.Wu, J., et al. Primary tumor surgery improves survival in non-metastatic primary urethral carcinoma patients: a large population-based investigation. BMC Cancer, 2021. 21: 857.
https://pubmed.ncbi.nlm.nih.gov/34315433/
62.Wenzel, M., et al. The effect of race/ethnicity on histological subtype distribution, stage at presentation and cancer specific survival in urethral cancer. Urol Oncol, 2021. 39: 369.e9.
https://pubmed.ncbi.nlm.nih.gov/33309509/
63.Champ, C.E., et al. Prognostic factors and outcomes after definitive treatment of female urethral cancer: a population-based analysis. Urology, 2012. 80: 374.
https://pubmed.ncbi.nlm.nih.gov/22857759/
64.Panettieri, V., et al. External Validation of a Predictive Model of Urethral Strictures for Prostate Patients Treated With HDR Brachytherapy Boost. Frontiers Oncol, 2020. 10: 910.
https://pubmed.ncbi.nlm.nih.gov/32596153/
65.Derksen, J.W., et al. Primary urethral carcinoma in females: an epidemiologic study on demographical factors, histological types, tumour stage and survival. World J Urol, 2013. 31: 147.
https://pubmed.ncbi.nlm.nih.gov/22614443/
66.Wenzel, M., et al. Comparison Between Urothelial and Non-Urothelial Urethral Cancer. Front Oncol, 2020. 10: 629692.
https://pubmed.ncbi.nlm.nih.gov/33585257/
67.Stone, B.V., et al. The effect of centralization of care on overall survival in primary urethral cancer. Urol Oncol: Sem Orig Invest, 2021. 39: 133.e17.
https://pubmed.ncbi.nlm.nih.gov/33268273/
68.Gakis, G., et al. The prognostic effect of salvage surgery and radiotherapy in patients with recurrent primary urethral carcinoma. Urol Oncol, 2018. 36: 10 e7.
https://pubmed.ncbi.nlm.nih.gov/29055518/
69.Dalbagni, G., et al. Male urethral carcinoma: analysis of treatment outcome. Urology, 1999. 53: 1126.
https://pubmed.ncbi.nlm.nih.gov/10367840/
70.Smith, Y., et al. Penile-preserving surgery for male distal urethral carcinoma. BJU Int, 2007. 100: 82.
https://pubmed.ncbi.nlm.nih.gov/17488307/
71.Pedrosa, J.A., et al. Distal urethrectomy for localized penile squamous carcinoma in situ extending into the urethra: an updated series. Int Urol Nephrol, 2014. 46: 1551.
https://pubmed.ncbi.nlm.nih.gov/24633698/
72.Kulkarni, M., et al. MP10-16 Substitution urethroplasty for treatment of distal urethral carcinoma and carcinoma in situ. J. Urol 193: e117.
https://www.auajournals.org/doi/full/10.1016/j.juro.2015.02.417
73.Torbrand, C., et al. Diagnosing Distal Urethral Carcinomas in Men Might Be Only the Tip of the Iceberg. Clin Genitourin Cancer, 2017. 15: e1131.
https://pubmed.ncbi.nlm.nih.gov/28784424/
74.Dimarco, D.S., et al. Surgical treatment for local control of female urethral carcinoma. Urol Oncol, 2004. 22: 404.
https://pubmed.ncbi.nlm.nih.gov/15464921/
75.DiMarco, D.S., et al. Outcome of surgical treatment for primary malignant melanoma of the female urethra. J Urol, 2004. 171: 765.
https://pubmed.ncbi.nlm.nih.gov/14713806/
76.Garden, A.S., et al. Primary carcinoma of the female urethra. Results of radiation therapy. Cancer, 1993. 71: 3102.
https://pubmed.ncbi.nlm.nih.gov/8490839/
77.Milosevic, M.F., et al. Urethral carcinoma in women: results of treatment with primary radiotherapy. Radiother Oncol, 2000. 56: 29.
https://pubmed.ncbi.nlm.nih.gov/10869752/
78.Zinman, L.N., et al. Management of Proximal Primary Urethral Cancer: Should Multidisciplinary Therapy Be the Gold Standard? Urol Clin North Am, 2016. 43: 505.
https://pubmed.ncbi.nlm.nih.gov/27717436/
79.Cahn, D.B., et al. Contemporary practice patterns and survival outcomes for locally advanced urethral malignancies: A National Cancer Database Analysis. Urol Oncol, 2017. 35: 670 e15.
https://pubmed.ncbi.nlm.nih.gov/28803701/
80.Dayyani, F., et al. Management of advanced primary urethral carcinomas. BJU Int, 2014. 114: 25.
https://pubmed.ncbi.nlm.nih.gov/24447439/
81.Peyton, C.C., et al. Survival Outcomes Associated With Female Primary Urethral Carcinoma: Review of a Single Institutional Experience. Clin Genitourin Cancer, 2018. 16: e1003.
https://pubmed.ncbi.nlm.nih.gov/29859736/
82.Mano, R., et al. Primary urethral cancer: treatment patterns and associated outcomes. BJU Int, 2020. 126: 359.
https://pubmed.ncbi.nlm.nih.gov/32336001/
83.Celtik, K., et al. Association Between Perioperative Chemotherapy and Survival in Men Undergoing Radical Resection for Primary Urethral Urothelial Carcinoma: An Analysis of the National Cancer Database. Clin Genitourin Cancer, 2022. 20: 244.
https://pubmed.ncbi.nlm.nih.gov/35181268/
84.Gakis, G., et al. Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma. Ann Oncol, 2015. 26: 1754.
https://pubmed.ncbi.nlm.nih.gov/25969370/
85.Kent, M., et al. Combined chemoradiation as primary treatment for invasive male urethral cancer.
J Urol, 2015. 193: 532.
https://pubmed.ncbi.nlm.nih.gov/25088950/
86.Gakis, G. Editorial Comment to Docetaxel, cisplatin and 5-fluorouracil chemotherapy with concurrent radiation for unresectable advanced urethral carcinoma. Int J Urol, 2014. 21: 424.
https://pubmed.ncbi.nlm.nih.gov/24251884/
87.Itoh, J., et al. Docetaxel, cisplatin and 5-fluorouracil chemotherapy with concurrent radiation for unresectable advanced urethral carcinoma. Int J Urol, 2014. 21: 422.
https://pubmed.ncbi.nlm.nih.gov/24251859/
88.Hara, I., et al. Successful treatment for squamous cell carcinoma of the female urethra with combined radio- and chemotherapy. Int J Urol, 2004. 11: 678.
https://pubmed.ncbi.nlm.nih.gov/15285764/
89.Cohen, M.S., et al. Coordinated chemoradiation therapy with genital preservation for the treatment of primary invasive carcinoma of the male urethra. J Urol, 2008. 179: 536.
https://pubmed.ncbi.nlm.nih.gov/18076921/
90.Son, C.H., et al. Optimizing the Role of Surgery and Radiation Therapy in Urethral Cancer Based on Histology and Disease Extent. Int J Radiat Oncol Biol Phys, 2018. 102: 304.
https://pubmed.ncbi.nlm.nih.gov/29908944/
91.Patschan, O., et al. Systematic Review of the Role of BCG in the Treatment of Urothelial Carcinoma of the Prostatic Urethra. Bladder Cancer, 2021. 7: 213.
https://content.iospress.com/articles/bladder-cancer/blc201516
92.Njinou Ngninkeu, B., et al. Transitional cell carcinoma involving the prostate: a clinicopathological retrospective study of 76 cases. J Urol, 2003. 169: 149.
https://pubmed.ncbi.nlm.nih.gov/12478124/
93.Hillyard, R.W., Jr., et al. Superficial transitional cell carcinoma of the bladder associated with mucosal involvement of the prostatic urethra: results of treatment with intravesical bacillus Calmette-Guerin. J Urol, 1988. 139: 290.
https://pubmed.ncbi.nlm.nih.gov/3339727/
94.Solsona, E., et al. The prostate involvement as prognostic factor in patients with superficial bladder tumors. J Urol, 1995. 154: 1710.
https://pubmed.ncbi.nlm.nih.gov/7563328/
95.Vazina, A., et al. Stage specific lymph node metastasis mapping in radical cystectomy specimens.
J Urol, 2004. 171: 1830.
https://pubmed.ncbi.nlm.nih.gov/15076287/
96.Galsky, M.D., et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. J Immunother Cancer, 2021. 9.
https://pubmed.ncbi.nlm.nih.gov/34266883/
97.Shukla, C.J., et al. Palliation of male genital cancers. Clin Oncol (R Coll Radiol), 2010. 22: 747.